209 related articles for article (PubMed ID: 19997103)
21. Phospho-STAT5 expression is associated with poor prognosis of human colonic adenocarcinoma.
Mao YL; Li ZW; Lou CJ; Pang D; Zhang YQ
Pathol Oncol Res; 2011 Jun; 17(2):333-9. PubMed ID: 21234733
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of the relationship of DNA mismatch repair with clinicopathologic features and prognosis of colon cancer].
Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
Zhonghua Zhong Liu Za Zhi; 2015 Aug; 37(8):591-6. PubMed ID: 26714599
[TBL] [Abstract][Full Text] [Related]
23. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
24. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
[TBL] [Abstract][Full Text] [Related]
25. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma.
Sinicrope FA; Rego RL; Ansell SM; Knutson KL; Foster NR; Sargent DJ
Gastroenterology; 2009 Oct; 137(4):1270-9. PubMed ID: 19577568
[TBL] [Abstract][Full Text] [Related]
26. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice.
Sasaki T; Kitadai Y; Nakamura T; Kim JS; Tsan RZ; Kuwai T; Langley RR; Fan D; Kim SJ; Fidler IJ
Neoplasia; 2007 Dec; 9(12):1066-77. PubMed ID: 18084614
[TBL] [Abstract][Full Text] [Related]
28. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas.
Sinicrope FA; Hart J; Hsu HA; Lemoine M; Michelassi F; Stephens LC
Clin Cancer Res; 1999 Jul; 5(7):1793-804. PubMed ID: 10430084
[TBL] [Abstract][Full Text] [Related]
29. Obesity is an independent prognostic variable in colon cancer survivors.
Sinicrope FA; Foster NR; Sargent DJ; O'Connell MJ; Rankin C
Clin Cancer Res; 2010 Mar; 16(6):1884-93. PubMed ID: 20215553
[TBL] [Abstract][Full Text] [Related]
30. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
Ohrling K; Edler D; Hallström M; Ragnhammar P
Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study.
Resnick MB; Routhier J; Konkin T; Sabo E; Pricolo VE
Clin Cancer Res; 2004 May; 10(9):3069-75. PubMed ID: 15131045
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
Hong KD; Lee SI; Moon HY
Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
[TBL] [Abstract][Full Text] [Related]
33. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Chouhan H; Sammour T; Thomas ML; Moore JW
J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
[TBL] [Abstract][Full Text] [Related]
34. United States Military Cancer Institute Clinical Trials Group (USMCI GI-01) randomized controlled trial comparing targeted nodal assessment and ultrastaging with standard pathological evaluation for colon cancer.
Nissan A; Protic M; Bilchik AJ; Howard RS; Peoples GE; Stojadinovic A
Ann Surg; 2012 Sep; 256(3):412-27. PubMed ID: 22871988
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
Soong R; Shah N; Salto-Tellez M; Tai BC; Soo RA; Han HC; Ng SS; Tan WL; Zeps N; Joseph D; Diasio RB; Iacopetta B
Ann Oncol; 2008 May; 19(5):915-9. PubMed ID: 18245778
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors in sporadic colon cancer with high-level microsatellite instability.
Oh BY; Huh JW; Park YA; Cho YB; Yun SH; Kim HC; Lee WY; Chun HK
Surgery; 2016 May; 159(5):1372-81. PubMed ID: 26775578
[TBL] [Abstract][Full Text] [Related]
37. Thymidylate synthase expression in colon carcinomas with microsatellite instability.
Sinicrope FA; Rego RL; Halling KC; Foster NR; Sargent DJ; La Plant B; French AJ; Allegra CJ; Laurie JA; Goldberg RM; Witzig TE; Thibodeau SN
Clin Cancer Res; 2006 May; 12(9):2738-44. PubMed ID: 16675565
[TBL] [Abstract][Full Text] [Related]
38. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
[TBL] [Abstract][Full Text] [Related]
39. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Roth AD; Delorenzi M; Tejpar S; Yan P; Klingbiel D; Fiocca R; d'Ario G; Cisar L; Labianca R; Cunningham D; Nordlinger B; Bosman F; Van Cutsem E
J Natl Cancer Inst; 2012 Nov; 104(21):1635-46. PubMed ID: 23104212
[TBL] [Abstract][Full Text] [Related]
40. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.
Niedzwiecki D; Bertagnolli MM; Warren RS; Compton CC; Kemeny NE; Benson AB; Eckhardt SG; Alberts S; Porjosh GN; Kerr DJ; Fields A; Rougier P; Pipas JM; Schwartz JH; Atkins J; O'Rourke M; Perry MC; Goldberg RM; Mayer RJ; Colacchio TA
J Clin Oncol; 2011 Aug; 29(23):3146-52. PubMed ID: 21747085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]